0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global HIV Prevention Drug Market Research Report 2026
Published Date: 2026-03-20
|
Report Code: QYRE-Auto-8W17797
Home | Market Reports | Health| Reproductive Health
Global HIV Prevention Drug Market Research Report 2024
BUY CHAPTERS

Global HIV Prevention Drug Market Research Report 2026

Code: QYRE-Auto-8W17797
Report
2026-03-20
Pages:105
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

HIV Prevention Drug Market

The global HIV Prevention Drug market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HIV Prevention Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for HIV Prevention Drug is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for HIV Prevention Drug is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of HIV Prevention Drug include Gilead Sciences, ViiV Healthcare, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global HIV Prevention Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HIV Prevention Drug. The HIV Prevention Drug market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global HIV Prevention Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist HIV Prevention Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of HIV Prevention Drug Market Report

Report Metric Details
Report Name HIV Prevention Drug Market
Segment by Type
  • Lenacapavir
  • Cabotegravir
by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences, ViiV Healthcare
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for HIV Prevention Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines HIV Prevention Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the HIV Prevention Drug Market report?

Ans: The main players in the HIV Prevention Drug Market are Gilead Sciences, ViiV Healthcare

What are the Application segmentation covered in the HIV Prevention Drug Market report?

Ans: The Applications covered in the HIV Prevention Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the HIV Prevention Drug Market report?

Ans: The Types covered in the HIV Prevention Drug Market report are Lenacapavir, Cabotegravir

1 HIV Prevention Drug Market Overview
1.1 Product Definition
1.2 HIV Prevention Drug by Type
1.2.1 Global HIV Prevention Drug Market Value by Type: 2025 vs 2032
1.2.2 Lenacapavir
1.2.3 Cabotegravir
1.3 HIV Prevention Drug by Application
1.3.1 Global HIV Prevention Drug Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global HIV Prevention Drug Market Size Estimates and Forecasts
1.4.1 Global HIV Prevention Drug Revenue 2021–2032
1.4.2 Global HIV Prevention Drug Sales 2021–2032
1.4.3 Global HIV Prevention Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 HIV Prevention Drug Market Competition by Manufacturers
2.1 Global HIV Prevention Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global HIV Prevention Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global HIV Prevention Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of HIV Prevention Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of HIV Prevention Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of HIV Prevention Drug, Product Types and Applications
2.7 Global Key Manufacturers of HIV Prevention Drug, Date of Entry into the Industry
2.8 Global HIV Prevention Drug Market Competitive Situation and Trends
2.8.1 Global HIV Prevention Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global HIV Prevention Drug Players Market Share by Revenue
2.8.3 Global HIV Prevention Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV Prevention Drug Market Scenario by Region
3.1 Global HIV Prevention Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global HIV Prevention Drug Sales by Region: 2021–2032
3.2.1 Global HIV Prevention Drug Sales by Region: 2021–2026
3.2.2 Global HIV Prevention Drug Sales by Region: 2027–2032
3.3 Global HIV Prevention Drug Revenue by Region: 2021–2032
3.3.1 Global HIV Prevention Drug Revenue by Region: 2021–2026
3.3.2 Global HIV Prevention Drug Revenue by Region: 2027–2032
3.4 North America HIV Prevention Drug Market Facts & Figures by Country
3.4.1 North America HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America HIV Prevention Drug Sales by Country (2021–2032)
3.4.3 North America HIV Prevention Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV Prevention Drug Market Facts & Figures by Country
3.5.1 Europe HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe HIV Prevention Drug Sales by Country (2021–2032)
3.5.3 Europe HIV Prevention Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Prevention Drug Market Facts & Figures by Region
3.6.1 Asia Pacific HIV Prevention Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific HIV Prevention Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific HIV Prevention Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV Prevention Drug Market Facts & Figures by Country
3.7.1 Latin America HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America HIV Prevention Drug Sales by Country (2021–2032)
3.7.3 Latin America HIV Prevention Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HIV Prevention Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Prevention Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa HIV Prevention Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa HIV Prevention Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV Prevention Drug Sales by Type (2021–2032)
4.1.1 Global HIV Prevention Drug Sales by Type (2021–2026)
4.1.2 Global HIV Prevention Drug Sales by Type (2027–2032)
4.1.3 Global HIV Prevention Drug Sales Market Share by Type (2021–2032)
4.2 Global HIV Prevention Drug Revenue by Type (2021–2032)
4.2.1 Global HIV Prevention Drug Revenue by Type (2021–2026)
4.2.2 Global HIV Prevention Drug Revenue by Type (2027–2032)
4.2.3 Global HIV Prevention Drug Revenue Market Share by Type (2021–2032)
4.3 Global HIV Prevention Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global HIV Prevention Drug Sales by Application (2021–2032)
5.1.1 Global HIV Prevention Drug Sales by Application (2021–2026)
5.1.2 Global HIV Prevention Drug Sales by Application (2027–2032)
5.1.3 Global HIV Prevention Drug Sales Market Share by Application (2021–2032)
5.2 Global HIV Prevention Drug Revenue by Application (2021–2032)
5.2.1 Global HIV Prevention Drug Revenue by Application (2021–2026)
5.2.2 Global HIV Prevention Drug Revenue by Application (2027–2032)
5.2.3 Global HIV Prevention Drug Revenue Market Share by Application (2021–2032)
5.3 Global HIV Prevention Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences HIV Prevention Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences HIV Prevention Drug Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare HIV Prevention Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 ViiV Healthcare HIV Prevention Drug Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Prevention Drug Industry Chain Analysis
7.2 HIV Prevention Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Prevention Drug Production Mode & Process Analysis
7.4 HIV Prevention Drug Sales and Marketing
7.4.1 HIV Prevention Drug Sales Channels
7.4.2 HIV Prevention Drug Distributors
7.5 HIV Prevention Drug Customer Analysis
8 HIV Prevention Drug Market Dynamics
8.1 HIV Prevention Drug Industry Trends
8.2 HIV Prevention Drug Market Drivers
8.3 HIV Prevention Drug Market Challenges
8.4 HIV Prevention Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global HIV Prevention Drug Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global HIV Prevention Drug Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global HIV Prevention Drug Market Competitive Situation by Manufacturers in 2025
 Table 4. Global HIV Prevention Drug Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global HIV Prevention Drug Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global HIV Prevention Drug Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global HIV Prevention Drug Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market HIV Prevention Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of HIV Prevention Drug, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of HIV Prevention Drug, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of HIV Prevention Drug, Product Types and Applications
 Table 12. Global Key Manufacturers of HIV Prevention Drug, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global HIV Prevention Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on HIV Prevention Drug Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global HIV Prevention Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global HIV Prevention Drug Sales by Region (K Units), 2021–2026
 Table 18. Global HIV Prevention Drug Sales Market Share by Region (2021–2026)
 Table 19. Global HIV Prevention Drug Sales by Region (K Units), 2027–2032
 Table 20. Global HIV Prevention Drug Sales Market Share by Region (2027–2032)
 Table 21. Global HIV Prevention Drug Revenue by Region (US$ Million), 2021–2026
 Table 22. Global HIV Prevention Drug Revenue Market Share by Region (2021–2026)
 Table 23. Global HIV Prevention Drug Revenue by Region (US$ Million), 2027–2032
 Table 24. Global HIV Prevention Drug Revenue Market Share by Region (2027–2032)
 Table 25. North America HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America HIV Prevention Drug Sales by Country (K Units), 2021–2026
 Table 27. North America HIV Prevention Drug Sales by Country (K Units), 2027–2032
 Table 28. North America HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
 Table 29. North America HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe HIV Prevention Drug Sales by Country (K Units), 2021–2026
 Table 32. Europe HIV Prevention Drug Sales by Country (K Units), 2027–2032
 Table 33. Europe HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific HIV Prevention Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific HIV Prevention Drug Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific HIV Prevention Drug Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific HIV Prevention Drug Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific HIV Prevention Drug Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America HIV Prevention Drug Sales by Country (K Units), 2021–2026
 Table 42. Latin America HIV Prevention Drug Sales by Country (K Units), 2027–2032
 Table 43. Latin America HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa HIV Prevention Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa HIV Prevention Drug Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa HIV Prevention Drug Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa HIV Prevention Drug Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa HIV Prevention Drug Revenue by Country (US$ Million), 2027–2032
 Table 50. Global HIV Prevention Drug Sales (K Units) by Type (2021–2026)
 Table 51. Global HIV Prevention Drug Sales (K Units) by Type (2027–2032)
 Table 52. Global HIV Prevention Drug Sales Market Share by Type (2021–2026)
 Table 53. Global HIV Prevention Drug Sales Market Share by Type (2027–2032)
 Table 54. Global HIV Prevention Drug Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global HIV Prevention Drug Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global HIV Prevention Drug Revenue Market Share by Type (2021–2026)
 Table 57. Global HIV Prevention Drug Revenue Market Share by Type (2027–2032)
 Table 58. Global HIV Prevention Drug Price (US$/Unit) by Type (2021–2026)
 Table 59. Global HIV Prevention Drug Price (US$/Unit) by Type (2027–2032)
 Table 60. Global HIV Prevention Drug Sales (K Units) by Application (2021–2026)
 Table 61. Global HIV Prevention Drug Sales (K Units) by Application (2027–2032)
 Table 62. Global HIV Prevention Drug Sales Market Share by Application (2021–2026)
 Table 63. Global HIV Prevention Drug Sales Market Share by Application (2027–2032)
 Table 64. Global HIV Prevention Drug Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global HIV Prevention Drug Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global HIV Prevention Drug Revenue Market Share by Application (2021–2026)
 Table 67. Global HIV Prevention Drug Revenue Market Share by Application (2027–2032)
 Table 68. Global HIV Prevention Drug Price (US$/Unit) by Application (2021–2026)
 Table 69. Global HIV Prevention Drug Price (US$/Unit) by Application (2027–2032)
 Table 70. Gilead Sciences Company Information
 Table 71. Gilead Sciences Description and Business Overview
 Table 72. Gilead Sciences HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Gilead Sciences HIV Prevention Drug Product
 Table 74. Gilead Sciences Recent Developments/Updates
 Table 75. ViiV Healthcare Company Information
 Table 76. ViiV Healthcare Description and Business Overview
 Table 77. ViiV Healthcare HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. ViiV Healthcare HIV Prevention Drug Product
 Table 79. ViiV Healthcare Recent Developments/Updates
 Table 80. Key Raw Materials Lists
 Table 81. Raw Materials Key Suppliers Lists
 Table 82. HIV Prevention Drug Distributors List
 Table 83. HIV Prevention Drug Customers List
 Table 84. HIV Prevention Drug Market Trends
 Table 85. HIV Prevention Drug Market Drivers
 Table 86. HIV Prevention Drug Market Challenges
 Table 87. HIV Prevention Drug Market Restraints
 Table 88. Research Programs/Design for This Report
 Table 89. Key Data Information from Secondary Sources
 Table 90. Key Data Information from Primary Sources
 Table 91. Authors List of This Report


List of Figures
 Figure 1. Product Picture of HIV Prevention Drug
 Figure 2. Global HIV Prevention Drug Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global HIV Prevention Drug Market Share by Type: 2025 & 2032
 Figure 4. Lenacapavir Product Picture
 Figure 5. Cabotegravir Product Picture
 Figure 6. Global HIV Prevention Drug Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global HIV Prevention Drug Market Share by Application: 2025 & 2032
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Others
 Figure 11. Global HIV Prevention Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global HIV Prevention Drug Market Size (US$ Million), 2021–2032
 Figure 13. Global HIV Prevention Drug Sales (K Units), 2021–2032
 Figure 14. Global HIV Prevention Drug Average Price (US$/Unit), 2021–2032
 Figure 15. HIV Prevention Drug Report Years Considered
 Figure 16. HIV Prevention Drug Sales Share by Manufacturers in 2025
 Figure 17. Global HIV Prevention Drug Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global HIV Prevention Drug Players: Market Share by Revenue in HIV Prevention Drug in 2025
 Figure 19. HIV Prevention Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global HIV Prevention Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America HIV Prevention Drug Sales Market Share by Country (2021–2032)
 Figure 22. North America HIV Prevention Drug Revenue Market Share by Country (2021–2032)
 Figure 23. United States HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe HIV Prevention Drug Sales Market Share by Country (2021–2032)
 Figure 26. Europe HIV Prevention Drug Revenue Market Share by Country (2021–2032)
 Figure 27. Germany HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific HIV Prevention Drug Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific HIV Prevention Drug Revenue Market Share by Region (2021–2032)
 Figure 34. China HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America HIV Prevention Drug Sales Market Share by Country (2021–2032)
 Figure 42. Latin America HIV Prevention Drug Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa HIV Prevention Drug Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa HIV Prevention Drug Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE HIV Prevention Drug Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of HIV Prevention Drug by Type (2021–2032)
 Figure 53. Global Revenue Market Share of HIV Prevention Drug by Type (2021–2032)
 Figure 54. Global HIV Prevention Drug Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of HIV Prevention Drug by Application (2021–2032)
 Figure 56. Global Revenue Market Share of HIV Prevention Drug by Application (2021–2032)
 Figure 57. Global HIV Prevention Drug Price (US$/Unit) by Application (2021–2032)
 Figure 58. HIV Prevention Drug Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI